IV Dextrose Management for Moderate Hypoglycemia

Initial Treatment

Administer a single 25‑gram intravenous dextrose bolus (e.g., 50 mL of 50 % dextrose) as the standard first‑line therapy for any patient with moderate hypoglycemia requiring parenteral treatment. 1

Initiate a continuous intravenous glucose infusion when the patient is unable to ingest oral carbohydrates, because the glycemic effect of a single IV bolus is short‑lived. 1
Switch to oral carbohydrate intake (a substantial snack or meal) as soon as the patient can safely swallow, to maintain euglycemia after the IV bolus. 1
Perform serial blood‑glucose monitoring after the bolus to evaluate the response and determine the need for additional therapy. 1

Avoid inducing post‑treatment hyperglycemia, especially after profound hypoglycemia, since experimental data suggest it may exacerbate neuronal injury. 1
Do not rely on a single bolus as definitive treatment; the glucose rise after IV dextrose typically wanes within two hours in insulin‑induced hypoglycemia. 1
Do not postpone treatment in patients who are unable or unwilling to take oral carbohydrates due to neuroglycopenic symptoms. 1

Hospitalize patients with sulfonylurea‑induced hypoglycemia for prolonged observation and treatment, because these episodes can be extended. 1
Consider using octreotide in cases of sulfonylurea overdose to help terminate the hypoglycemic episode. 1
Intravenous glucagon (1 mg) can be used as an alternative to dextrose, but it results in slower recovery of consciousness (approximately 6.5 min vs. 4 min with dextrose) and often produces transient hyperglycemia and gastrointestinal side effects. 1
Intravenous dextrose remains the preferred parenteral therapy for moderate hypoglycemia when administered by qualified medical personnel. 1

IV dextrose 25 g (50 mL of 50 % dextrose) remains the first‑line parenteral therapy for acute hypoglycemia. 2
Octreotide should be considered early in sulfonylurea overdose because these ingestions cause prolonged and recurrent hypoglycemia that often does not respond to dextrose alone. 2

The Endocrine Society Clinical Practice Guideline explicitly recognizes octreotide as a treatment option for sulfonylurea‑induced hypoglycemia, distinguishing it from other causes of hypoglycemia. 2

For adults with sulfonylurea‑induced hypoglycemia refractory to or recurring after initial IV dextrose, administer octreotide 50 µg subcutaneously every 6–12 hours; hospitalization is required for prolonged observation. 2

All patients with sulfonylurea‑induced hypoglycemia require hospitalization for extended observation because episodes can be prolonged and recurrent. 2

When the patient can safely swallow, provide oral carbohydrates (a substantial snack or meal) to maintain euglycemia while tapering IV dextrose. 2